Market Overview

JPMorgan Sees 'Shaxalta' Upside Potential At 36%

Share:
JPMorgan Sees 'Shaxalta' Upside Potential At 36%
Related
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable
Related
Shire Down 6% Since Brexit, Goldman Sachs Still Bullish
The Market In 5 Minutes: Happy Memorial Day Weekend

Following the acquisition of Baxalta Inc (NYSE: BXLT), JPMorgan’s James D. Gordon believes Shire PLC (ADR) (NASDAQ: SHPG) could have 36 percent upside.

Gordon maintains an Overweight rating on the company, while raising the price target from £53 to £56.

‘Shaxalta’s’ Hemophilia Potential

Adding Shire to JPMorgan’s Analyst Focus List, the analyst mentioned that a hemophilia deep dive suggested core EPS accretion of 4–6 percent during 2017–2020, with potential for double digit accretion beyond 2023.

“Within Baxalta, we believe the market has overly focused on the outlook for the hemophilia inhibitor franchise, and has overlooked the strong and sustainable outlook for Baxalta's non-hemophilia franchise,” Gordon stated.

Related Link: Short Sellers Dump Amgen And Baxalta

The analyst expects the market to take a more positive view over the next 12 months regarding the sustainability of the growth of the combined entity.

Overall, Gordon expects total hemophilia sales to remain almost flat during 2017-2020 and decline only in the single digits during 2020–2025.

The Non-Hemophilia Franchise

The analyst also believes that the robust outlook for Baxalta’s non-hemophilia franchise was being overlooked, especially the sustainability of revenue growth at 20 percent for the combined entity.

Gordon expects non-hemophilia products to grow at a CAGR of 10 percent during 2017–2020 and at 4 percent during 2020–2025.

“In particular, we see Baxalta’s HyQvia as the best in class IG, IG sales growing from $2.1 billion in 2017 to $2.8 billion by 2020,” the analyst pointed out.

Latest Ratings for SHPG

DateFirmActionFromTo
Dec 2016UBSDowngradesBuyNeutral
Sep 2016PiperJaffrayMaintainsNeutral
Jun 2016Goldman SachsMaintainsBuy

View More Analyst Ratings for SHPG
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Reiteration M&A Analyst Ratings

 

Related Articles (SHPG + BXLT)

View Comments and Join the Discussion!